ArticlePulmonary circulation
Care of patients with pulmonary arterial hypertension during the coronavirus (COVID-19) pandemic.
Article in Pulmonary circulation. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 65 citations in OpenAlex.
- Comparing Pulmonary Arterial Hypertension Care in Urban and Rural Settings:Pulmonary circulation · 2025Article
- The Role of Telehealth in PAH Management: Benefits, Barriers, and Solutions.Pulmonary circulation · 2025Article
- Sendaway capillary NT-proBNP in pulmonary hypertension.BMJ open respiratory research · 2024Article
- Remote exercise testing in pulmonary hypertension (PHRET).Pulmonary circulation · 2023Article
- Effects of COVID-19 pandemic on the management of pulmonary hypertension.Respiratory medicine · 2023Article
- Management of COVID-19 in Patients with Pulmonary Arterial Hypertension.Heart failure clinics · 2023Review
- Application of emetine in SARS-CoV-2 treatment: regulation of p38 MAPK signaling pathway for preventing emetine-induced cardiac complications.Cell cycle (Georgetown, Tex.) · 2022Article
- Towards telemedicine in pulmonary hypertension: Assessing the feasibility of remote quality of life and exercise capacity assessment.Pulmonary circulation · 2022Article
- Right Heart Catheterization-To Do or Not To Do? Introducing a New Diagnostic Algorithm for Pulmonary Hypertension.Journal of the American Heart Association · 2022Article
- Different Aspects of Emetine's Capabilities as a Highly Potent SARS-CoV-2 Inhibitor against COVID-19.ACS pharmacology & translational science · 2022Review
- Explanation of COVID-19 Mortality Using Artificial Neural Network Based on Underlying and Laboratory Risk Factors in Ilam, Iran.Archives of Razi Institute · 2022Article
- Outcomes of COVID-19 infection in pediatric pulmonary hypertension: A single-center experience.Pediatric pulmonology · 2021Article
- Cardiovascular Disease Complicating COVID-19 in the Elderly.Medicina (Kaunas, Lithuania) · 2021Review
- Identifying Barriers to and Opportunities for Telehealth Implementation Amidst the COVID-19 Pandemic by Using a Human Factors Approach: A Leap Into the Future of Health Care Delivery?JMIR human factors · 2021Article
- Clinical Presentation and Successful Management of an Infant With Down Syndrome and COVID-19 in Riyadh, Saudi Arabia.Cureus · 2021Article
- Alcohol use disorder: A pre-existing condition for COVID-19?Alcohol (Fayetteville, N.Y.) · 2021Review
- COVID-19 in Pulmonary Artery Hypertension (PAH) Patients: Observations from a Large PAH Center in New York City.Diagnostics (Basel, Switzerland) · 2021Article
- Impact of the 2019 Novel Coronavirus Disease Pandemic on the Performance of a Cardiovascular Department in a Non-epidemic Center in Beijing, China.Frontiers in cardiovascular medicine · 2021Article
- COVID-19 and Pulmonary Hypertension in Children: What Do We Know So Far?Medicina (Kaunas, Lithuania) · 2020Review
- A Survey-based Estimate of COVID-19 Incidence and Outcomes among Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension and Impact on the Process of Care.Annals of the American Thoracic Society · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The COVID-19 pandemic presents many unique challenges when caring for patients with pulmonary hypertension. The COVID-19 pandemic has altered routine standard of care practice and the acute management particularly for those patients with pulmonary arterial hypertension, where pulmonary arterial hypertension-specific treatments are used. It is important to balance the ongoing care and evaluation of pulmonary arterial hypertension patients with "exposure risk" to COVID-19 for patients coming to clinic or the hospital. If there is a morbidity and mortality benefit from starting pulmonary arterial hypertension therapies, for example in a patient with high-likelihood of pulmonary arterial hypertension, then it remains important to complete the thorough evaluation. However, the COVID-19 outbreak may also represent a unique time when pulmonary hypertension experts have to weigh the risks and benefits of the diagnostic work-up including potential exposure to COVID-19 versus initiating targeted pulmonary arterial hypertension therapy in a select high-risk, high likelihood World Symposium Pulmonary Hypertension Group 1 pulmonary arterial hypertension patients. This document will highlight some of the issues facing providers, patients, and the pulmonary arterial hypertension community in real-time as the COVID-19 pandemic is evolving and is intended to share expected common clinical scenarios and best clinical practices to help the community at-large.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.